Aseptic Necrosis of Femur HeadBMP7NCT02655120
Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult
A study testing Drilling and Bone Marrow +BMP7 in people with Aseptic Necrosis of Femur Head, run by University Hospital, Lille at 1 site in France.
Trial summary
The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Aseptic Necrosis of Femur Head
- What is being tested?
- Drilling and Bone Marrow +BMP7
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 41 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2005to May 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patient aged between 18 and 60 years male or female.
- Necrosis of the femoral head stage I to III FICAT (stage III with depression of less than 3 mm)
- Nontraumatic osteonecrosis
- Patient can undergo general anesthesia or locoregional
- Having given his consent
- Able to understand the constraints of the study
Who cannot join
- Refusing to participate in the study
- Active infection at the site
- Cancer changing
- Pregnancy
- Necrosis posttraumatic
- Having already undergone surgery on the surgical site
Show all 9Show fewer
- Contraindication to the practice of NMRI
- Contraindication to the use of OP1 (BMP7): collagen, arthritis, scleroderma, lupus
- Patient participating in another ongoing study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Efficiency of Autologous Bone Marrow no Concentrated to Associate at BMP7 Treatment of Necrosis of the Femoral Head of the Adult
The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT.
Read the detailed description
Rationale and Objectives Epiphyseal necrosis are common in young adults (2000 new cases per year in the Nord Pas -de- Calais region) resulting in severe functional impairment and disability . Drilling is the procedure most simple, but its effectiveness and safety are discussed ( fracture risk , long discharge period , success rates below 50 % until stage III). However, it can be optimized in two ways: 1) reducing morbidity and discharge period by reducing the diameter of the channel and percutaneous achievement , 2 ) increase efficiency , including coverage contribution of stem cells and osteogenic hormone . The purpose of this study is to test the effectiveness of the contribution of these elements to the healing necrosis .
Material, Method, and primary endpoint This is a prospective multicenter clinical trial randomized double-blind . The effect of addition of autologous bone marrow stem cells and BMP7 on healing necrosis is assessed by magnetic resonance imaging ( NMRI ) and is the primary endpoint . Patients are randomly assigned to two arms : 1 ) Group I: a simple drilling is practiced , 2 ) Group II : the drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 ( OP1 ) . Necrosis of the femoral head with stage I to III are retained Ficat (only stage III with a recess of less than 3 mm are used , corresponding I-III according to Steinberg ) . Forty patients are included in each arm . A IRMN practiced preoperatively and at 6 months and 2 years. Clinical evaluation will be continued up to 5 years in testing the survival rate ( criterion censorship = recovery by hip ) Expected results and possible implications In terms of radiological stabilization ( NMRI ) the effectiveness of single drilling necrosis stage I to III Ficat is 60 % ( non- stabilization or worsening of size). The hypothesis tested is a gain stabilization ( and / or recovery) of 20 % . The clinical efficacy of single drilling necrosis stage I to III Ficat is estimated at 50 % (50% recovery by prosthesis in 5 years) . The assumption is a 20% improvement in the rate of success of the intervention . Reducing morbidity due to technical modifications has been previously tested. If the assumption of success is reached, the indications of drilling could be reinforced especially for patients with multiple visceral defects usually supported on the websites of University Hospital of Lille and Amiens and CH Roubaix ( organ transplant or tissue , ethyl , .. ) .
- Conditions
- Aseptic Necrosis of Femur Head
- Being tested
- Drilling, Bone Marrow +BMP7
- Keywords
- Femoral head necrosis, Autologous Bone Marrow, BMP7
- Medical subject headings
- Femur Head Necrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DrillingProcedure or surgery
Bone Marrow +BMP7Biological
| Study group | Role | What they receive |
|---|---|---|
| Bone Marrow +BMP7 | Experimental | The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1) Receives: Biological: Bone Marrow +BMP7 |
| Drilling | Placebo comparator | Group I: a simple drill is practiced Receives: Procedure: Drilling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Necrosis volume
Varying the volume of necrosis in MRI, student test comparing the mean (independent samples).
Measured: 24 months
Secondary outcomes (3)
Merle d'aubigné hip score
variation of functional score, according to the two groups, by ANOVA repeated measures
Measured: 6 and 24 months
Measurement of radiographic stage variation between pre-operative and 24 months radiographies using concentric circles of Möse
Measured: 24 months
Comparison of hip survival by measuring the number of revisions for hip replacement in the 2 groups
Hip survival (= no revision for hip replacement) will be assessed using Kaplan-Meier curves and Logrank test.
Measured: 60 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2016 (estimated)
- Study startMar 2005
- Primary completionMay 2017
- Study completionMay 2017
Why it stopped: stopping the marketing of BMP7
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Aseptic Necrosis of Femur HeadStudies of the same condition, open and under way.
- More trials run by University Hospital, LilleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Lille
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Henri Migaud, MD, PhD, Study chair, University Hospital, Lille
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02655120
- Sponsor's protocol ID
- 2005-0503
- Other IDs
- TC 183
- Acronym
- BMP7
- Status last verified
- May 2018
- First submitted
- 12 Nov 2014
- Last updated
- 8 May 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Efficiency of Autologous Bone Marrow no Concentrated to Associate at BMP7 Treatment of Necrosis of the Femoral Head of the Adult
- ClinicalTrials.gov ID
- NCT02655120
- Acronym / sponsor ID
- BMP7 / 2005-0503
- Conditions
- Aseptic Necrosis of Femur Head
- Keywords
- Femoral head necrosis, Autologous Bone Marrow, BMP7
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: stopping the marketing of BMP7
- Enrolment
- 41 participants (actual)
- Lead sponsor
- University Hospital, LilleUniversity, hospital or other
- Study start
- Mar 2005
- Primary completion
- May 2017 (actual)
- Study completion
- May 2017 (actual)
- First posted
- 13 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of the study is to evaluate the effectiveness of the injection of bone marrow unconcentrated more R BMP 7 to repair necrosis of the femoral head with stage I-III classification FICAT.
Detailed description
Rationale and Objectives Epiphyseal necrosis are common in young adults (2000 new cases per year in the Nord Pas -de- Calais region) resulting in severe functional impairment and disability . Drilling is the procedure most simple, but its effectiveness and safety are discussed ( fracture risk , long discharge period , success rates below 50 % until stage III). However, it can be optimized in two ways: 1) reducing morbidity and discharge period by reducing the diameter of the channel and percutaneous achievement , 2 ) increase efficiency , including coverage contribution of stem cells and osteogenic hormone . The purpose of this study is to test the effectiveness of the contribution of these elements to the healing necrosis .
Material, Method, and primary endpoint This is a prospective multicenter clinical trial randomized double-blind . The effect of addition of autologous bone marrow stem cells and BMP7 on healing necrosis is assessed by magnetic resonance imaging ( NMRI ) and is the primary endpoint . Patients are randomly assigned to two arms : 1 ) Group I: a simple drilling is practiced , 2 ) Group II : the drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 ( OP1 ) . Necrosis of the femoral head with stage I to III are retained Ficat (only stage III with a recess of less than 3 mm are used , corresponding I-III according to Steinberg ) . Forty patients are included in each arm . A IRMN practiced preoperatively and at 6 months and 2 years. Clinical evaluation will be continued up to 5 years in testing the survival rate ( criterion censorship = recovery by hip ) Expected results and possible implications In terms of radiological stabilization ( NMRI ) the effectiveness of single drilling necrosis stage I to III Ficat is 60 % ( non- stabilization or worsening of size). The hypothesis tested is a gain stabilization ( and / or recovery) of 20 % . The clinical efficacy of single drilling necrosis stage I to III Ficat is estimated at 50 % (50% recovery by prosthesis in 5 years) . The assumption is a 20% improvement in the rate of success of the intervention . Reducing morbidity due to technical modifications has been previously tested. If the assumption of success is reached, the indications of drilling could be reinforced especially for patients with multiple visceral defects usually supported on the websites of University Hospital of Lille and Amiens and CH Roubaix ( organ transplant or tissue , ethyl , .. ) .
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bone Marrow +BMP7 | Experimental | Biological: Bone Marrow +BMP7The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1) |
| Drilling | Placebo comparator | Procedure: DrillingGroup I: a simple drill is practiced |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Patient aged between 18 and 60 years male or female.
- Necrosis of the femoral head stage I to III FICAT (stage III with depression of less than 3 mm)
- Nontraumatic osteonecrosis
- Patient can undergo general anesthesia or locoregional
- Having given his consent
Key exclusion criteria (9 listed)
- Refusing to participate in the study
- Active infection at the site
- Cancer changing
- Pregnancy
- Necrosis posttraumatic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Drilling | Procedure or surgery | Drilling |
| Bone Marrow +BMP7 | Biological | Bone Marrow +BMP7 |
Primary outcome
Necrosis volume
Time frame: 24 months
Varying the volume of necrosis in MRI, student test comparing the mean (independent samples).
3 secondary outcomes
Merle d'aubigné hip score
Time frame: 6 and 24 months
Measurement of radiographic stage variation between pre-operative and 24 months radiographies using concentric circles of Möse
Time frame: 24 months
Comparison of hip survival by measuring the number of revisions for hip replacement in the 2 groups
Time frame: 60 months
Results and safety
The study was stopped early (reason given: stopping the marketing of BMP7). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2018.
Related trials for Aseptic Necrosis of Femur Head
Recruiting
EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN))
Osteoarthritis, Traumatic Arthritis
RecruitingObservational study
Z1 Hip System: Post-Market Clinical Follow Up Study
Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck
Active, not recruiting
Avenir Complete Post-Market Clinical Follow-Up Study
Osteoarthritis, Hip, Avascular Necrosis of Hip
Active, not recruitingObservational study
The Medacta Quadra-P Anteverted Study
Arthrosis, Traumatic Arthritis
RecruitingObservational study
The Medacta International SMS Post-Marketing Surveillance Study
Arthrosis, Traumatic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Henri Migaud, MD, PhD study chair
University Hospital, Lille
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Drilling and Bone Marrow +BMP7 in people with Aseptic Necrosis of Femur Head, run by University Hospital, Lille at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 8 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: stopping the marketing of BMP7). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Necrosis volume (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2018.